Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final European